Performance indicators

Executive summary

Value higher than target
Value less than or equal to target
ItemEnglandScotlandWalesNorthern IrelandRepublic of IrelandUKIACR Average
Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2014 compared with 2013-0.2%-0.6%-1.7%-1.6%-0.5%-0.4%
Late Registrations: Percentage (%) for all cancers (C00-C97 ex. C44) of 2013 registrations at 01/01/2016 compared with registrations at 01/01/20152.1%2.5%2.3%1.9%3.3%2.2%
Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2014 registered cancers (C00-C97 ex. C44)76.7%51.3%66.8%80.0%42.6%63.5%
Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information99.2%95.4%90.5%87.5%99.6%94.2%
Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information97.4%98.3%94.0%97.0%96.5%96.6%
Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis97.7%94.0%98.5%96.7%91.8%95.8%
DCO Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO0.9%0.3%1.6%0.7%1.6%1.0%
Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis1.6%0.6%2.0%0.9%2.5%1.5%
Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified85.2%84.8%79.4%87.2%91.9%85.7%
Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes1.7%1.5%7.7%2.1%3.0%3.2%
Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade55.8%56.2%18.5%52.9%54.5%47.6%
Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment85.9%70.9%65.8%70.1%58.9%70.3%
Breast Screening Data: Percentage of breast cancer (C50) cases from 2014 screen detected for ages 50-6411.1%46.4%52.3%52.1%N/A40.5%
Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2014 screen detected for ages 60-6917.5%28.9%21.6%N/AN/A22.7%
Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2014 screen detected for ages 25-608.8%54.4%N/A28.1%N/A30.4%

Registrations and timeliness

Year England Scotland Wales Northern Ireland Republic of Ireland
2011 282,892 31,106 18,506 8,769 20,519
2012 288,607 31,336 18,430 9,029 20,583
2013 297,439 31,721 19,661 9,080 20,757
2013 (from Previous PI) 291,299 30,939 19,218 8,904 20,076
No. of 2014 not-finalised cases 1,050 482 N/A N/A N/A
No. of 2014 full cases 296,815 31,541 19,325 8,936 20,643
Registry creep 2.06% 2.47% 2.25% 1.94% 3.28%
Not-finalised cases 0.35% 1.53% 0.00% 0.00% 0.00%

No. of Cases (current year) and percentage change vs. previous year (persons)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 75,452 296,815 (2.5%) 31,541 (0.5%) 19,325 (2.4%) 8,936 (-0.3%) 20,643 (0.1%)
All xnmsc 0-24 852 3,389 (6.6%) 315 (12.1%) 191 (-2.1%) 122 (14.4%) 245 (-15.8%)
All xnmsc 25-59 17,937 69,635 (3.8%) 7,451 (1%) 4,102 (4%) 2,335 (0.2%) 6,160 (0.2%)
All xnmsc 60-79 40,139 156,872 (2.2%) 17,324 (0.6%) 10,633 (2.5%) 4,833 (0.9%) 11,031 (0.5%)
All xnmsc 80+ 16,533 66,919 (1.6%) 6,451 (-0.9%) 4,399 (1.1%) 1,689 (-4.8%) 3,205 (-0.1%)
Haematology 6,585 26,504 (3%) 2,345 (0.3%) 1,694 (7.7%) 734 (-1.7%) 1,648 (-1.6%)
Head and Neck 2,418 9,257 (2.9%) 1,232 (-3.1%) 657 (5.1%) 311 (-4.1%) 635 (1.6%)
Lower GI 9,331 36,332 (-1.7%) 3,960 (-5%) 2,527 (0%) 1,229 (-7%) 2,607 (-1.6%)
Upper GI 3,318 12,652 (-2.7%) 1,608 (-0.1%) 900 (2%) 449 (6%) 980 (5.8%)
HPB 3,652 14,367 (4.9%) 1,565 (3.6%) 914 (-1.1%) 423 (-3.5%) 993 (8.9%)
Trachea, Bronchus & Lung 9,709 37,436 (1.6%) 5,254 (0.1%) 2,422 (-1%) 1,214 (2.6%) 2,220 (-6.2%)
Melanoma 3,299 13,036 (11.2%) 1,244 (4.7%) 821 (10.4%) 351 (2.5%) 1,042 (9.7%)
Breast 11,674 46,411 (6.5%) 4,608 (-1.2%) 2,951 (10.2%) 1,301 (-1%) 3,099 (-0.5%)
Cervix 696 2,590 (-0.1%) 384 (22.6%) 167 (9.2%) 81 (-21.4%) 256 (-13.8%)
Other Female Genitals 3,877 15,278 (2.7%) 1,610 (5.8%) 1,038 (-0.8%) 483 (-0.8%) 978 (7.3%)
Prostate 9,970 39,714 (2.8%) 3,171 (-0.4%) 2,537 (1.3%) 1,119 (6.1%) 3,307 (-3.4%)
Kidney 2,526 10,325 (12.1%) 919 (4.7%) 503 (-4.7%) 312 (3.9%) 572 (-10.3%)
Bladder 2,112 8,511 (-5.3%) 840 (3%) 523 (-8.8%) 198 (-5.4%) 488 (14.3%)
Brain and CNS 1,137 4,386 (-2%) 445 (0.3%) 299 (3.8%) 149 (13.5%) 404 (8.5%)
Thyroid & other endocrine glands 805 3,205 (10.1%) 293 (5.4%) 135 (3.3%) 85 (-3.8%) 307 (-1.3%)
CUP 1,869 7,228 (-8.4%) 880 (4.7%) 553 (-3%) 201 (-2%) 481 (12.4%)
Other invasive cancer 2,474 9,583 (0.2%) 1,183 (6.4%) 684 (1.7%) 296 (3.1%) 626 (5.4%)
Breast in situ 1,669 6,850 (21.3%) 463 (-1%) 422 (33.4%) 164 (6.3%) 445 (9.6%)
Cervix in situ 6,773 26,017 (5.3%) 2,723 (5%) 1,926 (1.6%) 1,148 (-2.4%) 2,050 (-36.8%)
Other tumours 10,388 35,095 (-7.1%) 6,112 (-3.5%) 3,082 (5.8%) 3,116 (6.2%) 4,535 (1.3%)
Non-Melanoma Skin Cancer 28,961 115,266 (7.1%) 11,462 (4.8%) 4,223 (1.1%) 3,642 (0.7%) 10,214 (4.8%)

Percentage (%) of death certificate only cases (persons) for 2014

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 1.01% 0.88% 0.29% 1.58% 0.68% 1.64%
All xnmsc 0-24 0.19% 0.00% 0.00% 0.52% 0.00% 0.41%
All xnmsc 25-59 0.20% 0.13% 0.11% 0.17% 0.17% 0.41%
All xnmsc 60-79 0.57% 0.42% 0.17% 0.93% 0.31% 1.00%
All xnmsc 80+ 3.38% 2.76% 0.82% 4.52% 2.49% 6.33%
Haematology 1.11% 1.05% 0.13% 1.83% 0.54% 2.00%
Head and Neck 0.61% 0.23% 0.00% 0.91% 0.32% 1.57%
Lower GI 0.68% 0.70% 0.13% 1.11% 0.41% 1.04%
Upper GI 1.25% 0.80% 0.56% 1.11% 1.11% 2.65%
HPB 1.94% 1.80% 0.26% 2.08% 0.71% 4.83%
Trachea, Bronchus & Lung 1.60% 1.02% 0.36% 2.31% 0.66% 3.65%
Melanoma 0.12% 0.09% 0.00% 0.49% 0.00% 0.00%
Breast 0.36% 0.31% 0.13% 0.61% 0.31% 0.45%
Cervix 0.44% 0.35% 0.00% 0.60% 1.23% 0.00%
Other Female Genitals 0.76% 0.58% 0.37% 1.64% 0.21% 1.02%
Prostate 0.57% 0.71% 0.09% 0.99% 0.18% 0.88%
Kidney 1.08% 0.84% 0.22% 1.59% 0.64% 2.10%
Bladder 1.00% 1.02% 0.12% 1.72% 1.52% 0.61%
Brain and CNS 0.90% 0.73% 0.22% 0.33% 0.00% 3.22%
Thyroid & other endocrine glands 0.76% 0.37% 0.00% 1.48% 0.00% 1.95%
CUP 4.89% 5.78% 2.05% 7.78% 4.48% 4.37%
Other invasive cancer 2.38% 1.38% 1.10% 4.09% 4.39% 0.96%
Breast in situ 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cervix in situ 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other tumours 0.49% 1.07% 0.11% 1.20% 0.00% 0.04%
Non-Melanoma Skin Cancer 0.03% 0.02% 0.00% 0.05% 0.03% 0.04%

Percentage (%) of zero survival cases (persons)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 1.51% 1.55% 0.63% 1.98% 0.90% 2.50%
All xnmsc 0-24 0.27% 0.41% 0.00% 0.52% 0.00% 0.41%
All xnmsc 25-59 0.36% 0.34% 0.27% 0.29% 0.30% 0.60%
All xnmsc 60-79 0.93% 0.96% 0.46% 1.11% 0.46% 1.66%
All xnmsc 80+ 4.75% 4.25% 1.55% 5.73% 3.02% 9.20%
Haematology 1.68% 1.64% 0.43% 2.24% 0.95% 3.16%
Head and Neck 0.86% 0.39% 0.16% 1.07% 0.32% 2.36%
Lower GI 1.12% 1.42% 0.28% 1.19% 0.65% 2.07%
Upper GI 1.91% 1.75% 0.93% 1.44% 1.56% 3.88%
HPB 3.25% 3.37% 1.02% 3.28% 0.71% 7.85%
Trachea, Bronchus & Lung 2.38% 2.40% 0.88% 2.93% 1.07% 4.64%
Melanoma 0.12% 0.12% 0.00% 0.49% 0.00% 0.00%
Breast 0.41% 0.43% 0.15% 0.68% 0.31% 0.48%
Cervix 0.52% 0.50% 0.26% 0.60% 1.23% 0.00%
Other Female Genitals 1.14% 0.93% 0.81% 2.02% 0.21% 1.74%
Prostate 0.80% 0.91% 0.22% 1.22% 0.27% 1.39%
Kidney 1.84% 1.89% 0.65% 2.19% 0.96% 3.50%
Bladder 1.37% 1.55% 0.48% 2.29% 1.52% 1.02%
Brain and CNS 1.31% 1.32% 0.45% 0.33% 0.00% 4.46%
Thyroid & other endocrine glands 1.11% 0.69% 0.34% 2.22% 0.00% 2.28%
CUP 7.03% 8.94% 4.32% 9.58% 5.47% 6.86%
Other invasive cancer 3.40% 2.44% 1.69% 5.41% 5.07% 2.40%
Breast in situ 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cervix in situ 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other tumours 0.68% 1.52% 0.20% 1.49% 0.00% 0.18%
Non-Melanoma Skin Cancer 0.03% 0.02% 0.00% 0.05% 0.05% 0.05%

Percentage (%) of microscopically verified cases (persons)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 85.70% 85.22% 84.84% 79.35% 87.21% 91.86%
All xnmsc 0-24 90.28% 94.45% 97.46% 77.49% 94.26% 87.76%
All xnmsc 25-59 95.48% 96.06% 96.54% 91.54% 95.55% 97.71%
All xnmsc 60-79 88.82% 89.21% 87.87% 83.38% 89.70% 93.94%
All xnmsc 80+ 64.92% 64.13% 62.56% 58.33% 65.84% 73.76%
Haematology 83.97% 85.14% 96.67% 56.32% 89.78% 91.93%
Head and Neck 96.86% 97.30% 96.51% 96.35% 97.75% 96.38%
Lower GI 90.36% 89.42% 89.29% 87.26% 91.21% 94.63%
Upper GI 92.39% 93.07% 93.28% 88.78% 93.76% 93.06%
HPB 56.30% 51.75% 48.82% 46.39% 62.65% 71.90%
Trachea, Bronchus & Lung 72.73% 70.54% 69.45% 68.33% 71.83% 83.51%
Melanoma 99.22% 99.24% 100.00% 97.81% 99.43% 99.62%
Breast 98.64% 98.46% 98.98% 97.05% 99.46% 99.23%
Cervix 97.90% 97.53% 98.18% 95.81% 98.77% 99.22%
Other Female Genitals 93.68% 94.67% 92.61% 90.08% 96.69% 94.38%
Prostate 88.58% 86.04% 87.98% 84.12% 88.74% 96.01%
Kidney 75.88% 73.00% 76.71% 66.00% 82.37% 81.29%
Bladder 88.73% 91.15% 88.21% 82.98% 88.89% 92.42%
Brain and CNS 71.18% 71.39% 71.01% 64.21% 71.81% 77.48%
Thyroid & other endocrine glands 94.13% 96.22% 96.59% 91.85% 94.12% 91.86%
CUP 45.97% 49.38% 42.16% 26.40% 42.29% 69.65%
Other invasive cancer 86.01% 87.62% 82.33% 79.09% 88.85% 92.17%
Breast in situ 99.04% 99.97% 100.00% 96.68% 98.78% 99.78%
Cervix in situ 99.91% 100.00% 100.00% 99.58% 100.00% 99.95%
Other tumours 82.23% 88.34% 93.68% 56.49% 75.71% 96.91%
Non-Melanoma Skin Cancer 98.38% 99.78% 99.83% 93.30% 99.56% 99.43%

Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 3.19% 1.69% 1.52% 7.66% 2.08% 3.02%
All xnmsc 0-24 6.76% 1.06% 0.00% 30.41% 0.00% 2.33%
All xnmsc 25-59 2.59% 1.16% 0.90% 7.06% 1.26% 2.59%
All xnmsc 60-79 2.92% 1.47% 1.39% 6.96% 1.78% 3.01%
All xnmsc 80+ 5.10% 3.28% 3.25% 9.63% 5.13% 4.23%
Haematology 21.43% 0.97% 0.35% 96.65% 1.06% 8.12%
Head and Neck 1.75% 1.62% 0.76% 0.47% 2.96% 2.94%
Lower GI 1.30% 1.24% 0.79% 1.77% 0.98% 1.70%
Upper GI 1.97% 1.83% 1.87% 2.25% 1.19% 2.74%
HPB 5.73% 6.55% 6.41% 8.02% 0.38% 7.28%
Trachea, Bronchus & Lung 3.11% 3.17% 1.78% 3.38% 2.98% 4.21%
Melanoma 0.02% 0.00% 0.00% 0.12% 0.00% 0.00%
Breast 1.72% 1.11% 1.97% 0.28% 3.86% 1.37%
Cervix 1.53% 1.31% 0.80% 3.13% 1.25% 1.18%
Other Female Genitals 1.60% 1.27% 1.34% 1.50% 0.21% 3.68%
Prostate 0.60% 0.32% 0.65% 0.80% 0.91% 0.35%
Kidney 1.39% 1.49% 1.13% 1.81% 0.39% 2.15%
Bladder 1.23% 1.06% 0.40% 0.69% 1.14% 2.88%
Brain and CNS 0.27% 0.73% 0.00% 0.00% 0.00% 0.64%
Thyroid & other endocrine glands 2.57% 2.30% 3.89% 0.81% 1.25% 4.61%
CUP 22.42% 20.76% 15.36% 27.40% 25.88% 22.69%
Other invasive cancer 2.09% 1.33% 1.13% 1.11% 1.52% 5.37%
Breast in situ 0.56% 0.31% 0.00% 0.98% 0.62% 0.90%
Cervix in situ 0.17% 0.03% 0.00% 0.10% 0.00% 0.73%
Other tumours 11.45% 3.41% 2.57% 13.10% 38.15% 0.00%
Non-Melanoma Skin Cancer 0.29% 0.12% 0.03% 0.05% 0.83% 0.42%

Mortality : Incidence ratios

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 0.47 0.45 0.50 0.46 0.48 N/A
All xnmsc 0-24 0.13 0.13 0.13 0.11 0.14 N/A
All xnmsc 25-59 0.26 0.24 0.27 0.25 0.27 N/A
All xnmsc 60-79 0.45 0.42 0.48 0.44 0.46 N/A
All xnmsc 80+ 0.78 0.74 0.83 0.73 0.82 N/A
Haematology 0.42 0.40 0.44 0.39 0.47 N/A
Head and Neck 0.33 0.30 0.35 0.27 0.41 N/A
Lower GI 0.38 0.38 0.41 0.39 0.36 N/A
Upper GI 0.81 0.80 0.83 0.82 0.78 N/A
HPB 0.85 0.81 0.85 0.88 0.88 N/A
Trachea, Bronchus & Lung 0.79 0.76 0.78 0.81 0.79 N/A
Melanoma 0.16 0.15 0.14 0.18 0.15 N/A
Breast 0.22 0.21 0.21 0.20 0.25 N/A
Cervix 0.28 0.28 0.23 0.31 0.30 N/A
Other Female Genitals 0.40 0.36 0.41 0.39 0.42 N/A
Prostate 0.24 0.23 0.29 0.24 0.21 N/A
Kidney 0.39 0.32 0.44 0.47 0.31 N/A
Bladder 0.54 0.50 0.57 0.51 0.60 N/A
Brain and CNS 0.78 0.77 0.88 0.74 0.74 N/A
Thyroid & other endocrine glands 0.16 0.14 0.15 0.10 0.24 N/A
CUP 1.10 1.22 0.95 1.10 1.14 N/A
Other invasive cancer 0.77 0.82 0.78 0.67 0.80 N/A
Breast in situ 0.00 0.00 0.00 0.00 0.00 N/A
Cervix in situ 0.00 0.00 0.00 0.00 0.00 N/A
Other tumours 0.06 0.09 0.05 0.07 0.03 N/A
Non-Melanoma Skin Cancer 0.01 0.00 0.01 0.01 0.01 N/A

Completeness of the dataset (%) - demographics and diagnostic details

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Patient's name 100.00% 99.99% 100.00% 100.00% 100.00% 99.99%
Patient's address 99.60% 99.66% 100.00% 99.99% 100.00% 98.32%
Sex 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Ethnicity 45.52% 94.30% 63.54% 24.24% 0.00% N/A
Date of death (where dead) 99.93% 100.00% 100.00% 100.00% 100.00% 99.64%
Postcode 100.00% 100.00% 99.99% 99.99% 100.00% N/A
Date of birth 100.00% 100.00% 100.00% 100.00% 100.00% 99.99%
Unique health identifier 99.93% 99.84% 99.99% 99.95% 99.94% N/A
Anniversary (diagnosis) date 99.99% 99.93% 100.00% 100.00% 100.00% 100.00%
Site of primary growth 97.33% 97.50% 96.99% 96.96% 97.63% 97.58%
Type of growth 88.83% 90.00% 98.98% 73.28% 88.90% 93.00%
Behaviour of growth 99.91% 99.99% 99.71% 99.86% 100.00% 100.00%
Basis of diagnosis 97.90% 99.08% 99.87% 95.27% 98.85% 96.41%
Diagnosis with hospital 95.75% 97.71% 94.00% 98.54% 96.74% 91.77%

% of all cancer cases (xnmsc)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Treatment 70.32% 85.89% 70.95% 65.77% 70.13% 58.87%
No Treatment 20.95% 2.27% 28.84% 11.55% N/A 41.13%
Stage I and II patients receiving any treatment (%) 81.84% 93.78% 84.21% 71.48% 78.38% 81.33%

% of Cases treated with Surgery

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 42.88% 46.50% 42.59% 37.24% 46.69% 41.37%
All xnmsc 0-24 50.02% 52.55% 57.78% 42.41% 58.20% 39.18%
All xnmsc 25-59 58.36% 64.01% 61.56% 55.29% 57.99% 52.94%
All xnmsc 60-79 41.64% 46.16% 40.89% 37.01% 45.54% 38.58%
All xnmsc 80+ 27.05% 28.78% 24.51% 20.75% 32.33% 28.89%
Haematology 10.29% 12.04% 5.54% 13.70% 9.54% 10.62%
Head and Neck 45.19% 51.26% 46.51% 44.44% 44.69% 39.06%
Lower GI 63.01% 65.00% 67.90% 53.66% 71.20% 57.31%
Upper GI 24.56% 34.42% 16.11% 8.44% 42.32% 21.53%
HPB 35.13% 29.81% 13.55% 50.00% 45.15% 37.16%
Trachea, Bronchus & Lung 17.44% 17.85% 12.77% 13.05% 24.63% 18.92%
Melanoma 79.21% 91.43% 97.35% 75.03% 56.98% 75.24%
Breast 72.79% 75.66% 78.62% 68.38% 76.71% 64.57%
Cervix 50.25% 62.55% 30.21% 50.90% 56.79% 50.78%
Other Female Genitals 67.90% 71.44% 70.62% 64.35% 64.39% 68.71%
Prostate 16.57% 21.03% 17.53% 12.81% 11.35% 20.11%
Kidney 56.08% 57.83% 52.34% 47.12% 70.51% 52.62%
Bladder 72.52% 82.63% 79.17% 73.42% 75.76% 51.64%
Brain and CNS 50.31% 45.53% 52.13% 35.12% 58.39% 60.40%
Thyroid & other endocrine glands 75.33% 79.44% 81.57% 68.15% 82.35% 65.15%
CUP 11.07% 11.21% 5.68% 6.15% 20.90% 11.43%
Other invasive cancer 48.75% 50.92% 49.79% 39.18% 53.04% 50.80%
Breast in situ 80.80% 85.12% 92.66% 78.20% 75.00% 73.03%
Cervix in situ 64.71% 87.10% 84.65% 60.96% 10.02% 80.83%
Other tumours 53.88% 59.41% 62.16% 41.69% 48.33% 57.82%
Non-Melanoma Skin Cancer 66.86% 48.53% 90.53% 78.59% 44.15% 72.50%

% of Cases treated with Radiotherapy

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 18.82% 19.46% 21.74% 9.15% 26.15% 17.57%
All xnmsc 0-24 11.99% 13.19% 15.24% 5.76% 13.93% 11.84%
All xnmsc 25-59 22.06% 21.41% 26.39% 11.17% 31.69% 19.64%
All xnmsc 60-79 20.45% 22.01% 23.48% 9.97% 28.24% 18.56%
All xnmsc 80+ 10.53% 11.78% 12.03% 5.46% 12.73% 10.64%
Haematology 8.25% 9.06% 9.72% 3.01% 11.04% 8.43%
Head and Neck 49.80% 53.61% 50.08% 30.90% 64.95% 49.45%
Lower GI 11.68% 12.26% 12.42% 6.61% 13.02% 14.12%
Upper GI 14.72% 17.08% 15.49% 10.44% 7.35% 23.27%
HPB 2.25% 2.30% 2.04% 1.31% 0.95% 4.63%
Trachea, Bronchus & Lung 27.62% 26.82% 33.84% 17.05% 37.15% 23.24%
Melanoma 1.25% 1.12% 1.13% 0.85% 0.85% 2.30%
Breast 33.34% 34.60% 40.93% 10.81% 52.42% 27.94%
Cervix 40.22% 35.95% 50.78% 26.35% 40.74% 47.27%
Other Female Genitals 15.46% 14.22% 18.57% 10.40% 19.25% 14.83%
Prostate 15.27% 18.05% 11.51% 4.26% 30.21% 12.31%
Kidney 6.74% 5.29% 5.98% 3.98% 10.58% 7.87%
Bladder 12.68% 14.73% 15.00% 7.07% 17.17% 9.43%
Brain and CNS 44.31% 41.09% 48.99% 25.08% 53.69% 52.72%
Thyroid & other endocrine glands 28.27% 32.73% 22.53% 23.70% 47.06% 15.31%
CUP 9.88% 11.15% 9.66% 7.05% 13.43% 8.11%
Other invasive cancer 11.81% 15.52% 12.93% 5.85% 14.53% 10.22%
Breast in situ 31.37% 28.67% 42.98% 6.64% 43.29% 35.28%
Cervix in situ 0.07% 0.02% 0.00% 0.00% 0.26% 0.05%
Other tumours 1.37% 0.96% 0.44% 0.75% 4.17% 0.51%
Non-Melanoma Skin Cancer 1.29% 1.21% 0.51% 2.08% 1.65% 1.01%

% of Cases treated with Teletherapy

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 19.88% 17.36% N/A N/A 25.56% 16.71%
All xnmsc 0-24 10.17% 9.65% N/A N/A 10.66% 10.20%
All xnmsc 25-59 22.32% 17.91% N/A N/A 30.49% 18.56%
All xnmsc 60-79 21.80% 19.90% N/A N/A 27.87% 17.63%
All xnmsc 80+ 11.41% 11.23% N/A N/A 12.55% 10.45%
Haematology 9.39% 8.69% N/A N/A 11.04% 8.43%
Head and Neck 53.25% 45.34% N/A N/A 64.95% 49.45%
Lower GI 12.11% 9.23% N/A N/A 13.02% 14.08%
Upper GI 15.05% 14.77% N/A N/A 7.13% 23.27%
HPB 2.51% 1.95% N/A N/A 0.95% 4.63%
Trachea, Bronchus & Lung 28.62% 25.87% N/A N/A 36.74% 23.24%
Melanoma 1.40% 1.05% N/A N/A 0.85% 2.30%
Breast 38.15% 34.21% N/A N/A 52.34% 27.88%
Prostate 18.85% 16.13% N/A N/A 30.03% 10.40%
Cervix 35.43% 23.36% N/A N/A 40.74% 42.19%
Other Female Genitals 11.68% 9.27% N/A N/A 17.60% 8.18%
Kidney 7.87% 5.15% N/A N/A 10.58% 7.87%
Bladder 13.53% 14.01% N/A N/A 17.17% 9.43%
Brain and CNS 46.59% 33.36% N/A N/A 53.69% 52.72%
Thyroid & other endocrine glands 7.41% 7.93% N/A N/A 9.41% 4.89%
CUP 10.33% 10.45% N/A N/A 12.44% 8.11%
Other invasive cancer 12.07% 12.61% N/A N/A 13.85% 9.74%
Breast in situ 35.72% 28.58% N/A N/A 43.29% 35.28%
Cervix in situ 0.08% 0.02% N/A N/A 0.17% 0.05%
Other tumours 1.76% 0.84% N/A N/A 3.98% 0.46%
Non-Melanoma Skin Cancer 1.26% 1.16% N/A N/A 1.62% 1.01%

% of Cases treated with Chemotherapy

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 21.42% 25.10% 25.81% 17.58% 22.21% 16.41%
All xnmsc 0-24 43.83% 55.71% 58.41% 38.74% 44.26% 22.04%
All xnmsc 25-59 33.84% 38.60% 42.60% 29.28% 36.40% 22.31%
All xnmsc 60-79 21.36% 25.81% 25.44% 18.09% 20.96% 16.50%
All xnmsc 80+ 5.31% 7.83% 5.84% 4.52% 4.03% 4.34%
Haematology 37.25% 53.34% 55.48% 31.35% 13.08% 33.01%
Head and Neck 21.41% 25.07% 25.73% 26.94% 15.11% 14.17%
Lower GI 25.85% 29.68% 30.61% 20.06% 25.79% 23.13%
Upper GI 34.72% 39.68% 36.13% 30.78% 44.54% 22.45%
HPB 21.16% 24.55% 20.00% 15.75% 26.95% 18.53%
Trachea, Bronchus & Lung 23.80% 28.33% 26.15% 20.77% 22.32% 21.44%
Melanoma 1.31% 0.83% 0.96% 2.07% 2.28% 0.38%
Breast 28.96% 31.60% 31.86% 20.98% 36.43% 23.94%
Cervix 30.22% 25.79% 47.40% 23.95% 32.10% 21.88%
Other Female Genitals 27.28% 28.93% 34.29% 19.17% 35.82% 18.20%
Prostate 1.25% 1.13% 1.07% 0.67% 3.04% 0.33%
Kidney 6.64% 8.09% 2.83% 6.36% 7.69% 8.22%
Bladder 21.79% 26.01% 27.14% 22.94% 23.23% 9.63%
Brain and CNS 22.96% 20.52% 30.56% 16.39% 29.53% 17.82%
Thyroid & other endocrine glands 3.77% 4.02% 4.44% 3.70% 4.71% 1.95%
CUP 8.38% 12.34% 8.18% 5.79% 8.96% 6.65%
Other invasive cancer 23.49% 29.56% 27.13% 18.71% 30.07% 11.98%
Breast in situ 2.74% 1.64% 1.94% 0.47% 8.54% 1.12%
Cervix in situ 0.05% 0.01% 0.00% 0.00% 0.26% 0.00%
Other tumours 7.36% 9.26% 11.08% 4.57% 9.92% 1.96%
Non-Melanoma Skin Cancer 0.30% 0.07% 0.39% 0.12% 0.88% 0.04%

% of Cases for other treatments

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
% of Cases treated with Hormone Therapy
All invasive xnmsc 10.90% 12.25% 15.43% 4.47% 16.83% 5.50%
Breast 39.72% 37.70% 64.45% 12.67% 61.57% 22.20%
Prostate 37.69% 45.50% 52.73% 19.08% 58.09% 13.06%
% of Cases treated with Brachytherapy
All invasive xnmsc 1.05% 1.03% N/A N/A 0.76% 1.36%
Breast 0.10% 0.11% N/A N/A 0.08% 0.13%
Prostate 2.17% 2.14% N/A N/A 1.97% 2.42%
% of Cases treated with Watch & Wait/Active Monitoring
All invasive xnmsc 3.60% 7.05% N/A N/A N/A 0.16%
Prostate 11.13% 21.81% N/A N/A N/A 0.45%
% of Cases treated with Palliative Care
All invasive xnmsc 4.42% 6.34% N/A N/A 6.83% 0.10%

Specific cohorts where treatment completeness data is expected (%)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
% of children and young adults (0-24 group) with cancer & underwent any treatment 81.29% 91.53% 93.33% 89.01% 76.23% 56.33%
% of all stage 1 cancer patients (exc. Brain and CNS tumours) who received any treatment 83.23% 92.82% 81.78% 75.71% 74.19% 91.66%
% of men under 60 with prostate cancer & received hormone treatment 19.26% 21.51% 30.55% 6.20% 31.90% 6.15%
% of men under 60 with cancer (C00-C97 exc. C44) & received hormone treatment 3.15% 3.72% 3.79% 0.99% 5.49% 1.75%
% of women under 60 with breast cancer & received hormone treatment 29.18% 22.81% 49.76% 3.41% 51.91% 18.01%
% of all haematological cancer patients who received any treatment 51.42% 82.12% 61.92% 41.09% 28.47% 43.51%

Quality of treatment data

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour):
Date of surgery known 100.00% 99.98% 100.00% 100.00% 100.00% 100.00%
Trust / hospital of surgery known 99.81% 99.74% 100.00% 100.00% 100.00% 99.32%
Type of surgery known (OPCS4 code) 100.00% 100.00% N/A 100.00% 100.00% 100.00%
Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour):
Date of teletherapy known 99.95% 99.86% N/A N/A 100.00% 100.00%
Trust / hospital of teletherapy known 99.96% 99.90% N/A N/A 100.00% 99.97%
Fractions and dose known 100.00% N/A N/A N/A 100.00% N/A
Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour):
Date of chemotherapy known 99.94% 99.68% 100.00% 100.00% 100.00% 100.00%
Trust / hospital of chemotherapy known 99.97% 99.90% 100.00% 100.00% 100.00% 99.94%
Drug name or regimen known 78.41% N/A N/A N/A 58.19% 98.64%
Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour):
Date of radiotherapy known 99.97% 99.85% 100.00% 100.00% 100.00% 100.00%
Trust / hospital of radiotherapy known 99.97% 99.90% 100.00% 100.00% 100.00% 99.97%

Completeness of the dataset (%) - Breast screening information

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Breast cancer - % screen detected for ages 50-64 (data 2014) 40.49% 11.12% 46.38% 52.33% 52.13% N/A
Breast cancer - % screen detected for ages 50-64 (last year, 2013) 44.27% 47.31% 49.88% 31.78% 48.12% N/A
Breast cancer - % with full screening history for ages 50-64 (data 2014) 77.17% 21.43% 99.94% 88.50% 98.82% N/A
Breast cancer - % with full screening history for ages 50-64 (last year, 2013) 86.33% 88.87% 99.94% 57.63% 98.90% N/A

Completeness of the dataset (%) - Cervical screening information

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Cervical cancer - % screen detected for ages 25-60 (data 2014) 30.45% 8.79% 54.42% N/A 28.13% N/A
Cervical cancer - % screen detected for ages 25-60 (last year, 2013) 34.40% 27.14% 53.45% N/A 22.62% N/A
Cervical cancer - % with full screening history for ages 25-60 (data 2014) 70.33% 11.34% 99.66% N/A 100.00% N/A
Cervical cancer - % with full screening history for ages 25-60 (last year, 2013) 88.98% 66.94% 100.00% N/A 100.00% N/A

Completeness of the dataset (%) - Bowel screening information

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
Bowel cancer - % screen detected for ages 60-69 (data 2014) 22.66% 17.49% 28.93% 21.56% N/A N/A
Bowel cancer - % screen detected for ages 60-69 (last year, 2013) 25.22% 25.85% 27.52% 21.04% 26.49% N/A
Bowel cancer - % with full screening history for ages 60-69 (data 2014) 76.95% 69.45% 99.89% 61.53% N/A N/A
Bowel cancer - % with full screening history for ages 60-69 (last year, 2013) 90.55% 98.12% 99.90% 64.48% 99.70% N/A

Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 63.50% 76.7% 51.3% 66.8% 80.0% 42.6%
All xnmsc 0-24 N/A N/A N/A N/A N/A N/A
All xnmsc 25-59 N/A N/A N/A N/A N/A N/A
All xnmsc 60-79 N/A N/A N/A N/A N/A N/A
All xnmsc 80+ N/A N/A N/A N/A N/A N/A
Haematology 32.60% 60.3% 0.0% 0.2% 66.6% 35.8%
Head and Neck 58.55% 83.2% 0.0% 79.5% 94.5% 35.6%
Lower GI 77.70% 87.0% 76.0% 87.6% 89.6% 48.3%
Upper GI 58.91% 77.5% 44.9% 77.1% 64.4% 30.7%
HPB 56.44% 59.7% 50.3% 47.7% 72.5% 52.0%
Trachea, Bronchus & Lung 75.66% 90.2% 78.5% 87.2% 91.2% 31.2%
Melanoma 59.38% 91.1% 0.0% 80.8% 98.0% 27.1%
Breast 83.02% 89.6% 83.3% 80.2% 93.3% 68.7%
Cervix 73.33% 70.6% 94.3% 43.1% 93.8% 64.8%
Other Female Genitals 64.06% 84.1% 28.8% 66.8% 88.1% 52.5%
Prostate 73.75% 87.6% 69.8% 79.4% 86.2% 45.7%
Kidney 70.15% 79.9% 63.6% 80.4% 92.3% 34.6%
Bladder 58.76% 81.4% 0.0% 72.5% 85.9% 54.1%
Brain and CNS N/A N/A N/A N/A N/A N/A
Thyroid and other endocrine glands 57.31% 62.5% 0.0% 79.5% 98.6% 45.9%
CUP N/A N/A N/A N/A N/A N/A
Other invasive cancer 41.84% 52.4% 3.9% 47.7% 66.0% 39.2%
Breast in situ N/A N/A N/A N/A N/A N/A
Cervix in situ N/A N/A N/A N/A N/A N/A
Other tumours N/A N/A N/A N/A N/A N/A
Non-Melanoma Skin Cancer 11.26% 6.8% 0.0% 12.7% 36.7% 0.0%

Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)

Table No. & Parameters UKIACR average England Scotland Wales Northern Ireland Republic of Ireland
All invasive xnmsc 47.59% 55.8% 56.2% 18.5% 52.9% 54.5%
All xnmsc 0-24 25.33% 24.9% N/A N/A 23.8% 27.3%
All xnmsc 25-59 52.64% 62.7% N/A N/A 59.8% 35.4%
All xnmsc 60-79 52.54% 60.1% N/A N/A 56.4% 41.2%
All xnmsc 80+ 35.71% 40.4% N/A N/A 34.3% 32.4%
Haematology 15.97% 5.5% 39.6% 0.7% 5.0% 28.9%
Head and Neck 61.10% 78.5% 83.1% 26.6% 62.1% 55.3%
Lower GI 62.69% 78.1% 79.7% 43.9% 38.5% 73.3%
Upper GI 60.62% 75.6% 76.4% 19.3% 66.6% 65.1%
HPB 23.88% 26.3% 23.6% 6.8% 28.4% 34.3%
Trachea, Bronchus & Lung 24.94% 28.7% 28.2% 7.7% 30.8% 29.4%
Melanoma 0.35% 0.7% 0.4% 0.2% 0.0% 0.4%
Breast 76.86% 94.4% 88.7% 31.8% 93.5% 76.0%
Cervix 68.31% 75.2% 82.3% 56.9% 72.8% 54.3%
Other Female Genitals 64.15% 60.6% 72.5% 44.3% 80.1% 63.2%
Prostate 65.08% 73.0% 85.9% 2.3% 87.0% 77.3%
Kidney 56.46% 59.0% 58.6% N/A 59.0% 49.3%
Bladder 72.17% 83.8% 79.9% 53.9% 84.8% 58.4%
Brain and CNS 75.18% 64.2% N/A N/A 83.9% 77.5%
Thyroid and other endocrine glands 10.20% 20.4% 6.8% 1.6% 15.3% 6.8%
CUP 22.07% 20.5% N/A N/A 17.4% 28.3%
Other invasive cancer 21.43% 24.1% 25.2% 5.9% 25.3% 26.7%
Breast in situ 30.34% 3.6% N/A N/A N/A 57.1%
Cervix in situ 5.56% 2.2% N/A N/A N/A 8.9%
Other tumours 21.46% 31.9% N/A N/A N/A 11.0%
Non-Melanoma Skin Cancer 18.13% 16.3% 25.8% 27.1% 0.8% 20.7%

The performance indicators measure registry performance for the five registries of the United Kingdom & Ireland Association of Cancer Registries:

  1. National Cancer Registry Ireland
  2. Northern Ireland Cancer Registry
  3. Public Health England
  4. Scottish Cancer Registry
  5. Welsh Cancer Intelligence & Surveillance Unit

A detailed commentary of the findings for each registry may be found at this link.

An Excel download of the complete results tables may be found at this link.

Building 6800
Cork Airport Business Park
Kinsale Road, Cork T12 CDF7
Email Contact us here
Tel: +353 (0) 21 4318014
Fax: +353 (0) 21 4318016

Location map
Go to top